Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis - Takeaways - MDSpire

Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis

  • By

  • Yan Wang

  • Xiaoyan Wang

  • Guihong Yu

  • Libao Zhang

  • Changhui Xue

  • Wanchen Gong

  • Jiashou Luo

  • Chengwu Lu

  • Linfeng Wang

  • July 9, 2026

  • 0 min

Share

  • 1

    Postmenopausal osteoporosis increases fracture risk, particularly in the lumbar spine, femoral neck, and total hip.

  • 2

    A Bayesian network meta-analysis evaluated the efficacy and safety of ABA, TER, OBP, IBP, DEN, and PLA/CTRL in postmenopausal women.

  • 3

    ABA showed the greatest improvement in lumbar spine and femoral neck BMD, while also being superior for total hip BMD.

  • 4

    TER and OBP had the lowest risk for adverse events, while ABA and PLA/CTRL showed the lowest risk for serious adverse events.

  • 5

    Anabolic agents significantly improved BMD at the spine and femoral neck, whereas antiresorptive agents were more effective for hip BMD.

Original Source(s)

Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis

  • by Yan Wang, Xiaoyan Wang, Guihong Yu, Libao Zhang, Changhui Xue, Wanchen Gong, Jiashou Luo, Chengwu Lu, Linfeng Wang

  • July 9, 2026

Related Content

Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease

Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits

Correction: Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report